Information Provided By: 
Fly News Breaks for March 28, 2017
TSRO, MYGN
Mar 28, 2017 | 06:31 EDT
Deutsche Bank analyst Dan Leonard says FDA approval of Tesaro's (TSRO) Zejula, with a "broad rather than biomarker-limited label," removes one potential upside catalyst for Myriad Genetics (MYGN). While some investors are surprised by the broad label, many had already discounted the possibility of a label that limited usage to biomarker positive patients, which would have benefited test-supplier Myriad, Leonard tells investors in a research note. The analyst keeps a Sell rating on Myriad with a $15 price target.
News For MYGN;TSRO From the Last 2 Days
